APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
HR 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act, Title I, Subtitle A, Section 101, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework; S. 1895, the Lower Health Care Costs Act, Title II, Section 205, Preventing Blocking of Generic Drugs, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework; and Federal policy relating to pharmaceutical market blockages caused by parked Hatch-Waxman 180-day exclusivity periods
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.